




PHARMACEUTICAL 2020

DYNAVAX TECHNOLOGIES CORP
Rank 278 of 358





PHARMACEUTICAL 2020

DYNAVAX TECHNOLOGIES CORP Rank 278 of 358



The relative strengths and weaknesses of DYNAVAX TECHNOLOGIES CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of DYNAVAX TECHNOLOGIES CORP compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 16% points. The greatest weakness of DYNAVAX TECHNOLOGIES CORP is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 150% points.

The company's Economic Capital Ratio, given in the ranking table, is -50%, being 87% points below the market average of 36%.

| Input Variable | Value in 1000 USD |
|---|-------------------|
| Assets, Current | 208,653 |
| Cost of Goods Sold | 0 |
| Intangible Assets | 4,581 |
| Liabilities, Current | 53,047 |
| Liabilities, Non-Current | 217,731 |
| Other Assets | 33,812 |
| Other Compr. Net Income | -372 |
| Other Expenses | 57,222 |
| Other Liabilities | 0 |
| Other Net Income | 4,101 |
| Other Revenues | 37,838 |
| Property and Equipment | 32,022 |
| Research and Development | 62,331 |
| Selling, General and Administrative Expense | 74,986 |

| Output Variable | Value in 1000 USD |
|--------------------------|-------------------|
| Assets | 279,068 |
| Liabilities | 270,778 |
| Expenses | 194,539 |
| Revenues | 37,838 |
| Stockholders Equity | 8,290 |
| Net Income | -152,600 |
| Comprehensive Net Income | -152,786 |
| Economic Capital Ratio | -50% |